Lamotrigine requires long taper up due to SJS risk. Lithium is problematic in a 78 year old with CKD stage 2

The short version: the retrieval does not contain a direct comparison of lamotrigine or lithium against olanzapine for mood stabilization in a 78-year-old with CKD stage 2, so the swap rests on indirect evidence and mechanism, not a head-to-head test.

Lamotrigine carries a real and well-documented risk of Stevens-Johnson syndrome (SJS), a severe skin reaction that can be fatal. The US FAERS analysis found lamotrigine had a reporting odds ratio of 53.0 for SJS/TEN compared to other drugs [2]. The risk is highest in the first two months and with rapid dose escalation [1]. A 78-year-old would need a slow taper up over weeks to months, which is the standard recommendation to minimize risk [1]. The retrieval contains no study testing whether that slow titration is safe or feasible in a geriatric patient already on multiple sedating drugs.

Lithium is problematic in CKD stage 2 because the kidneys clear it. The retrieval contains no study of lithium in stage 2 CKD, but the mechanism is clear: reduced clearance means higher blood levels for a given dose, and lithium toxicity damages the kidneys further. The retrieval does not provide a safe dosing protocol for this situation.

The retrieval contains no study of any mood stabilizer in a 78-year-old with CKD stage 2. The 2006 lamotrigine weight study [3] and the 2009 lithium review [4] studied younger adults without renal impairment. The 2008 quetiapine naturalistic study [5] included patients with a mean age of about 52, not 78.

My call: neither lamotrigine nor lithium is supported by evidence for this specific patient. Lamotrigine's SJS risk demands a slow titration that has not been tested in this age group, and lithium's renal clearance is a known problem in CKD. The evidence does not show a safe, effective swap. Confidence: low, because the retrieval lacks any study in this exact population.